Moderna does not plan to initiate another mRNA-1403 cohort this season
A Phase 3 interim analysis of mRNA-1403 did not meet statistical criteria for early success.
Related stories
Sunstone Hotel Q3 Revenue Beats Estimates, Raises FY Outlook
M impact | EQUITY | Nov 06, 2026, 12:43 PM UTC
TELUS Reports C$660 Million Q3 Loss, Reaffirms 2026 Guidance
TELUS reported a third-quarter net loss of C$660 million, or C$0.42 per basic share, versus net income of C$431 million, or C$0.32 per share, a year earlier. The company also reaff
M impact | EQUITY | Nov 06, 2026, 12:42 PM UTC
Soligenix Q3 Net Loss Narrows on Lower R&D Costs
M impact | EQUITY | Nov 06, 2026, 12:39 PM UTC
Moderna Swings to Third-Quarter Profit and Raises Full-Year Revenue Outlook
Moderna reported a profit in the recent quarter and lifted its full-year revenue forecast as international demand for its Covid-19 vaccines stabilized.
M impact | EQUITY | Nov 06, 2026, 12:33 PM UTC
Baytex Energy Reports Q3 2026 Results, Targets Growth Through 2029
Baytex reported third-quarter production of 71,606 boe/d and net cash of $522 million. Its updated plan targets 8%–10% annual production growth through 2029 and commits $150 millio
M impact | EQUITY | Nov 06, 2026, 12:33 PM UTC
Elanco Reports Q3 2026 Revenue of $1.265 Billion, Updates Outlook
Elanco reported revenue up 11% year over year and 9% organic constant currency growth. Adjusted net income was $136 million, adjusted EPS was $0.27 and adjusted EBITDA was $243 mil
M impact | EQUITY | Nov 06, 2026, 12:33 PM UTC